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Abstract
Background: The net charge of the hypervariable V3 loop on the HIV-1 envelope gp120 outer domain plays a key role in
modulating viral phenotype. However, the molecular mechanisms underlying the modulation remain poorly understood.
Methodology/Principal Findings: By combining computational and experimental approaches, we examined how V3 net
charge could influence the phenotype of the gp120 interaction surface. Molecular dynamics simulations of the identical
gp120 outer domain, carrying a V3 loop with net charge of +3o r+7, showed that the V3 change alone could induce global
changes in fluctuation and conformation of the loops involved in binding to CD4, coreceptor and antibodies. A
neutralization study using the V3 recombinant HIV-1 infectious clones showed that the virus carrying the gp120 with +3 V3,
but not with +7 V3, was resistant to neutralization by anti-CD4 binding site monoclonal antibodies. An information entropy
study shows that otherwise variable surface of the gp120 outer domain, such as V3 and a region around the CD4 binding
loop, are less heterogeneous in the gp120 subpopulation with +3 V3.
Conclusions/Significance: These results suggest that the HIV-1 gp120 V3 loop acts as an electrostatic modulator that
influences the global structure and diversity of the interaction surface of the gp120 outer domain. Our findings will provide
a novel structural basis to understand how HIV-1 adjusts relative replication fitness by V3 mutations.
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Introduction
The third variable (V3) element of the human immunodefi-
ciency virus type 1 (HIV-1) envelope gp120 protein is usually
composed of 35 amino acids. The element forms a protruding
loop-like structure on the gp120 outer domain [1], is rich in basic
amino acids, and has aromatic amino acids for the aromatic
stacking interaction with proteins. The V3 loop participates in
direct binding to the entry coreceptor [2] and constitutes the
most critical determinant for the coreceptor use of HIV-1
[3,4,5,6]. In addition, the tip of V3 is highly immunogenic and
contains neutralization epitopes for antibodies [7,8,9], although
the epitopes can be inaccesible in the gp120 trimer on a virion of
the HIV-1 primary isolates [10,11] or HIV-1 recombinants with
less positively charged V3 [12,13]. Moreover, the V3 is reported
to be the major determinant of HIV-1 sensitivity to neutraliza-
tion by the soluble form of CD4 [14,15,16], a recombinant
protein that binds to the cleft of the gp120 core [17]. Thus, the
V3 loop plays a key role in modulating biological and
immunological phenotypes of HIV-1. However, the molecular
mechanisms underlying these modulations remain poorly
understood.
It has been reported that the net charge of the V3 loop is tightly
linked to the phenotype of HIV-1. The V3 loops of CCR5 tropic
HIV-1s are usually less positively charged than those of CXCR4
tropic HIV-1s [18,19,20,21]. An increase in the V3 net charge can
convert CCR5 tropic viruses into CXCR4 tropic viruses
[4,22,23,24], and antibody resistant viruses into sensitive viruses
[12,13]. Thus the V3 loop may be viewed as an electrostatic
modulator of the structure of the gp120 interaction surface, an
assumption that is largely unexamined.
Increasing evidence has indicated that the dynamics property
of molecules in solution is critical for protein function and thus
for many biological processes [25,26,27]. Molecular dynamic
(MD) simulation is a powerful method that predicts the structural
dynamics of biological molecules in solution, which is often
difficult to analyze by experiments alone [28,29,30]. Recent
advances in biomolecular simulation have rapidly improved the
precision and application performance of this technique
[28,29,30]. We have previously applied this technique to
investigating the structural factors that regulate biological
phenotype of viruses [13,31,32]. In this study, by combining
MD simulations with antibody neutralization experiments and
diversity analysis of the viral protein sequences, we studied a
structural basis for the regulation of HIV-1 phenotype by V3
loop.
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Molecular dynamics simulation study
To address the potential role of the V3 net charge in modulating
the structure and dynamics of the gp120 surface, we performed
MD simulations of the identical gp120 outer domains carrying
different V3 loops with net charges of +7o r+3 (Fig. 1A). The
initial structures for the simulations were constructed by homology
modeling using the crystal structure of HIV-1 gp120 containing an
entire V3 loop as the template. Due to the perfect identity of the
outer domain sequences of the V3 recombinant gp120s, the outer
domain structures of the initial models for the MD simulations
were identical before the simulations. The modeling targets in this
study belong to HIV-1 subtype B and had a sequence similarity of
about 87.3% to the modeling template. This similarity was high
enough to construct high-accuracy models with an RMSD of
,1.5 A ˚ for the main chain between the predicted and actual
structures in the tested cases with homology models and x-ray
crystal structures [33]. These initial models were lacking in V1/V2
loops and glycans on the gp120. The recombinant models are
therefore suitable for exploring the potency of the structural
regulation that is intrinsic to the V3 loop.
Using these models as the initial structures, we analyzed the
structural dynamics of the gp120 outer domains in the absence of
soluble CD4 by MD simulation. It was expected that the MD
simulations would eliminate initial distortions in the template
crystal structure, which could be generated during crystallization,
and search for the most stable structures of unliganded gp120
outer domains at 1 atm at 310 K in water. The simulations
showed that the same gp120 outer domains, carrying different V3
loops with net charges of +7o r+3, exhibited marked changes in
conformations and fluctuations at several functional loops at 1 atm
at 310 K in water (Figs. 1 and 2).
To quantitatively monitor the overall structural dynamics of the
outer domain during MD simulation, the RMSDs between the
initial model and models at given times of MD simulation were
measured. The RMSD sharply increased soon after heating of the
initial model and then gradually reached a near plateau after 10 ns
of the MD simulations (Fig. 1B). The results suggested that most of
the backbone heavy atoms of the outer domain reached a
thermodynamic equilibrium after 10 ns of the simulation under
the conditions employed. However, fluctuations of the RMSDs
were still detectable even at around 30 ns of the simulations,
suggesting that some regions of the outer domains continued to
fluctuate.
To map the heavily fluctuating sites in the gp120 outer domain,
we calculated the RMSF of the main chains of individual amino
acids during the MD simulations. The RMSFs, which provide
information about the atomic fluctuations during MD simulations
[34], were found to be much greater in the amino acids
constituting loops than those of the structured regions, such as
helixes and b-sheets (Figs. 1C and 1D). These results are consistent
with the general observations of proteins in solution, and indicate
that the loops of the gp120 outer domain intrinsically possess
structural flexibility in water. Notably, the RMSFs in some loops
were markedly different between the two V3 recombinant gp120s.
For example, the RMSF in the b20–b21 loop was much greater in
the Gp120LAI-TH09V3 (Fig. 1C). Conversely, those in the D loop
were greater in the Gp120LAI-NH1V3.
HIV-1 gp120 V3 loop often has a motif for the N-linked
glycosylation that is usually preferentially conserved in R5 viruses
(Fig. 1A). To address potential impacts of the glycan on the MD
simulations, we performed MD simulation in the presence of a
high mannose oligosaccharide in the V3 loop. We observed any
significant differences in the structure and dynamics of gp120
outer domain in the presence or absence of the glycan (data not
shown). This is reasonable because the glycosylation site is exposed
toward an opposite direction from the gp120 core (Fig. 1D).
To clarify structural differences between the Gp120LAI-NH1V3
and Gp120LAI-TH09V3, we constructed their averaged structures
using the 40,000 snapshots obtained from 10–30 ns of MD
simulations using ptraj module in Amber 9. Superposition of the
averaged structures showed that the relative configuration of the
V3 loops and b20–b21 was markedly different between the two
outer domains: the V3 tip protruded a greater distance from the
b20–b21 loop in the Gp120LAI-TH09V3 than in the Gp120LAI-
NH1V3 (Fig. 2A). The superposed structures also revealed
differences in a region around the CD4 binding site (Fig. 2A,
right panel with enlarged CD4 binding site). The relative
configuration of the CD4 binding loop to the exit loop is critical
for the gp120 binding to the CD4, a primary infection receptor of
HIV-1 [17]. Therefore, we analyzed the distance between the
CD4 binding and exit loops by measuring the distance (D115–221)
between the Ca of Gly115 and the Ca of Gly221 as an indicator
(Fig. 2B). As expected from the fluctuations of the CD4 binding
loop, the D115–221 fluctuated during the MD simulations (Fig. 2C).
However, the D115–221 was significantly smaller in the Gp120LAI-
TH09V3 than in the Gp120LAI-NH1V3 (Fig. 2D; p,0.001, Student’s
t-test): the D115–221 ranged from 4–15 A ˚ with an average of ,8A ˚
for the Gp120LAI-TH09V3 and from 7–17 A ˚ with an average of
,10 A ˚ for the Gp120LAI-NH1V3. These data suggest that the CD4
binding loop tended to be positioned more closely to the exit loop
and thus tended to be sterically less exposed in the Gp120LAI-
TH09V3 than the Gp120LAI-NH1V3.
Neutralization study
The above structural data raised the possibility that the
reduction in the V3 net charge might reduce HIV-1 neutralization
sensitivity by the anti-CD4 binding site antibodies. To address this
possibility, we performed a neutralization assay using the two
isogenic HIV-1 recombinant viruses, HIV-1LAI-NH1V3 and HIV-
1LAI-TH09V3 [35], which carry the Gp120LAI-NH1V3 and Gp120LAI-
TH09V3, respectively. These viruses were pre-incubated with
various human MAbs against the CD4 binding site, and the
reductions in viral infectious titers were measured using a HeLa-
cell-based single-round viral infectivity assay system [36].
Table 1 summarizes the results of the neutralization assay. As
expected, the two viruses exhibited markedly distinct neutraliza-
tion sensitivities to the three human MAbs against the CD4
binding site. HIV-1LAI-NH1V3 was consistently neutralized with all
three MAbs against the CD4 binding site (49G2, 42F6, and 0.5d),
with ND50 values ranging between 0.224 and 0.934 mg/ml. In
marked contrast, HIV-1LAI-TH09V3 was highly resistant to
neutralization by these MAbs, and 10 mg/ml of antibodies failed
to block the viral infections. The two viruses were equally resistant
to an anti-Gp120 antibody (4C11) that recognizes the Gp120
structure after CD4 binding. The result indicates that the CD4-
induced gp120 epitope of the 4C11 are not preserved in the V3
recombinant viruses used in the present study. Conversely, they
were equally sensitive to another ant-Gp120 antibody (4301 [37])
whose epitope is located outside of the CD4 binding site. A human
MAb 8D11 used as a negative control had no effect on the viral
infectivity in this assay.
Diversity study
Host immunity is a driving force behind the antigenic diversity
of envelope proteins of the primate lentiviruses that establish
persistent infection in hosts [23,38,39,40,41]. The above and
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bility that the gp120 surface might be less heterogeneous in gp120
subpopulations that have a less positively charged V3 loop, due to
greater magnitudes of resistance to the antibody neutralization. To
address this possibility, we performed an information entropy
study using sequences in the public database. We extracted full-
length gp120 amino acid sequences of HIV-1 subtype CRF01_AE
that has the same evolutionary origin and is spread throughout
southeast Asia [42]), and divided them into subgroups on the basis
of the net charge of V3 loop (+2, +3, +4, +5, +6, +7, and +8). The
sequences were used to calculate the Shannon entropy scores, H(i)
[1], to denote the diversity of individual amino acids within each
subpopulation.
Figure 3 shows the 3-D distribution of the H(i) scores of
individual amino acids plotted on the HIV-1 gp120 crystal
structure (PDB code: 2B4C [1]), where the green to orange regions
were suggested to have more variable amino acids than the blue
ones. In the gp120 subpopulation that has +7 V3 loop, the H(i)
scores often exceeded 2.0 bits at many residues, reaching close to
the maximum value of 4.4, i.e., the diversity was maximal, at the
V5 region (Fig. 3A, left panel). Regions with high H(i) scores
included the functional sites, such as the V3 loop and the regions
around the CD4 binding site. In marked contrast, in the gp120
subpopulation carrying the +3 V3 loop, the H(i) scores were
almost zero, i.e., the diversity was minimal, at many amino acids,
but not at those in the V4, V5, and LE regions (Fig. 3A, right
panel). Importantly, relatively high levels of conservation were also
detected with amino acids in the otherwise highly variable V3
loop. Moreover, a region adjacent to the CD4 binding loop was
also less heterogeneous compared with those of the gp120
subpopulation carrying +7 V3 loop (Figs. 3B). In the gp120
subpopulations carrying the +2, +3, 4, and +5 V3 loops, the H(i)
scores were indistinguishable from each other: they were less
heterogeneous than the subpopulations carrying the +6, +7, and
+8 V3 loops. Similar results were obtained with HIV-1 subtype C
that represents the most predominated HIV-1 in the world (data
not shown).
Discussion
The ability of HIV-1 to rapidly change its phenotype greatly
complicates our efforts to eradicate this virus. Elucidation of
structural principles for the phenotypic change may provide a clue
to control HIV-1. In this study, by combining MD simulations
with antibody neutralization experiments and diversity analysis of
the viral protein sequences, we studied a structural basis for the
phenotypic change of HIV-1 by V3 mutations. To address this
issue, we used a V3 recombinant system; we performed a
computer-assisted structural study and an infection-based neutral-
ization assay using gp120 proteins whose amino acid sequences are
identical except for V3 loop. In combination with an informatics
study, we obtained evidence that the HIV-1 V3 loop acts as an
electrostatic modulator that influences the global structure and
diversity of the interaction surface of the gp120 outer domain.
Using MD simulation, we first examined whether the V3 net
charge could affect the structural dynamics of the HIV-1 gp120
outer domain surface. Initial structures of the outer domain of the
two gp120s, Gp120LAI-NH1V3 and Gp120LAI-TH09V3, were identi-
cal before MD simulations, because the domains were both
derived from HIV-1LAI strain. Remarkably, however, the two
molecules with distinct V3 loop exhibited markedly distinct
structural dynamics following MD simulations (Figs. 1 and 2).
These data strongly suggest that the V3 net charge can act as an
intrinsic modulator that influences the structural dynamics of the
interaction surface of the gp120 outer domain. Such a global effect
on structure by a local electrostatic change has been reported with
bacteriorhodopsin [43]. In general, the long-range effects of non-
electrostatic contributions are negligible, whereas those of the
electrostatic contributions are not [34]. Therefore, it is reasonable
that the changes in overall charge of the V3 loop element caused
the global effects on the gp120 structure via alteration of the
electrostatic potentials of the gp120 surface.
We next studied biological impact of the structural changes
predicted by MD simulations. The MD simulations suggested that
the CD4 binding loop was less exposed in the Gp120LAI-NH1V3
than the Gp120LAI-NH1V3 (Fig. 2). The finding predicted that
reduction in V3 net charge could cause reduction in neutralization
sensitivity to the anti-CD4 binding site antibodies. This possibility
was assessed by neutralization assay. We used infectious HIV-1LAI
clones having the Gp120LAI-NH1V3 or the Gp120LAI-TH09V3 to
assess their neutralization sensitivities to the anti-CD4 binding site
MAbs. Notably, we indeed observed marked reduction in the
neutralization sensitivity in HIV-1LAI having Gp120LAI-TH09V3
(Table 1). The results are consistent with the structural changes
predicted by MD simulations, as well as previous findings on
neutralization sensitivity of HIV-1s to soluble CD4 [14,15,16].
We further studied evolutionary impact predicted by MD
simulations and the neutralization studies. These studies predicted
that reduction in V3 net charge could cause reduction in sequence
diversity around the CD4 binding site due to reduced sensitivity to
positive selection pressures of antibodies. Notably, we indeed
observed marked reduction in the gp120 diversity: our Shannon
entropy data show that otherwise variable surfaces of gp120, such
as V3 and a region around the CD4 binding loop, are less
heterogeneous in the gp120 subgroups carrying a V3 loop with a
+3 charge (Fig. 3).
Previous cryo-electron microscopy studies have indicated that
gp120 forms a trimer on an HIV-1 virion, where the CD4 binding
sites are exposed on the outside surface in the solution [44,45,46].
Therefore, it is reasonable that gp120 with +3 V3 with less
exposed CD4 binding loop is less sensitive to neutralization by
anti-CD4 binding site antibodies (Table 1) and less heterogeneous
around the CD4 binding site (Fig. 3). Collectively, our results
Figure 1. MD simulation of the identical gp120 outer domain carrying a V3 loop with net charge of +7o r+3. (A) Schematic
representation of the gp120 open reading frame along with the amino acid sequences. The net charge indicates the number of positively charged
amino acids (R, K, and H) minus the number of negatively charged amino acids (D and E) in the V3 loop. A light blue box indicates the outer domain
used for the MD simulations. A pink box indicates the V3 loop. The numbers indicate amino acid positions at the outer domain (amino acids 1 to 233
in Figure 1A correspond to amino acids 256 to 489 in the gp120 of HIV-1LAI) or the V3 loop. An open black box in the V3 loop sequence indicates a
potential site for the N-linked glycosylation. (B–D) Left panels: Gp120LAI-NH1V3; Right panels: Gp120LAI-TH09V3. +7 and +3 indicate the net charges of V3
loops of the recombinant proteins. (B) Time course of RMSD during MD simulations. The RMSD values indicate the structural fluctuations of the outer
domain in aqueous solution. The numbers in the horizontal axes indicate the time of MD simulation. (C) Distribution of RMSF in the gp120 outer
domain. The RMSF values indicate the atomic fluctuations of the main chains of individual amino acids during 10–30 ns of MD simulations. The
numbers in the horizontal axes indicate amino acid positions at the outer domain. (D) Superimposition of Gp120 models at 10, 15, 20, 25, and 30 ns
of MD simulation. A green asterisk indicates approximate position of a potential N-glycosylation site at the V3 stem. A green arrow indicates the site
of the disulfide bond at the V3 base.
doi:10.1371/journal.pone.0037530.g001
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suggest that V3 net charge is an intrinsic factor that influences
structural property, antibody sensitivity, and sequence diversity of
CD4 binding site.
The HIV-1 gp120 outer domain has several functional or
immunogenic loops involved in binding to CD4, coreceptor and
antibodies. Our MD simulations predicted that V3 net charge
influences fluctuation and conformation of these loops (Figs. 1 and
2). The V3-based structural modulation of the gp120 surface loops
may be an effective mechanism to alter effectively the phenotype
and relative fitness of HIV-1. For example, a change in the V3 net
charge by mutations may induce changes in V3 conformation
(Figs. 1D and 2A) [13], which in turn may influence intra- or inter-
molecular interactions among gp120 monomers and thus global
structure of gp120 trimer on a virion. Generation of a swarm of
structural variants by V3 mutations could help generating the best-
Figure 2. Comparison of the averaged 3-D models during MD simulation. (A) Superposition of the averaged structures obtained with the
40,000 snapshots obtained from 10–30 ns of MD simulations using ptraj module in Amber 9. Red and Blue ribbons: loops of Gp120LAI-NH1V3 and
Gp120LAI-TH09V3 with V3 net charges of +7 and +3, respectively. (B–D) Configuration and structural dynamics of the CD4 binding loop. The distance
between the Ca of Gly115 and the Ca of Gly221 in the CD4 binding loop was calculated to monitor configurational changes (B). The distance was
monitored during the 10–30 ns of MD simulation (C) and the average distance with variance was plotted (D). +7: Gp120LAI-NH1V3; +3: Gp120LAI-TH09V3.
doi:10.1371/journal.pone.0037530.g002
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Antibody ID Ig subtype Epitopes on Gp120 ND50 (mg/ml)
@
HIV-1LAI-NH1V3 HIV-1LAI-TH09V3
49G2 human IgG1 CD4 binding site
# 0.224 .10
42F9 human IgG1 CD4 binding site
# 0.934 .10
0.5d [59] human IgG1 CD4 binding site
# 0.444 .10
4C11 [59] human IgG2 CD4 induced structure
$ .20 .10
4301 mouse IgG broadly reactive* 0.59 0.57
8D11 human IgG1 none .20 .10
#Neutralization epitope in the Gp120 outer domain before CD4 binding.
$Neutralization epitope induced in Gp120 after CD4 binding.
*Epitopes outside of the CD4 binding site [37].
@The effect of each antibody on viral infectivity was tested in duplicate.
doi:10.1371/journal.pone.0037530.t001
Figure 3. Diversity of the gp120 subpopulations carrying a V3 loop with net charge of +7o r+3. Full-length gp120 sequences of the HIV-1
CRF01_AE [42] were extracted from a public database, and divided into subgroups on the basis of the net charge of the V3 loop (+2,+8). The divided
sequences were used to calculate the Shannon entropy, H(i) [63], within each subpopulation, and the H(i) values were plotted on the 3-D structure of
gp120 (PDB code: 2B4C [1]). The results for the gp120 subgroups that have V3 loops with +7 (left panel) and +3 (right panel) charges are shown as
representative. The numbers of sequences used to calculate the H(i) were 9 and 81 for +7 and +3, respectively. (A) Distribution of H(i) in the gp120
monomer. (B) Distribution of H(i) around the CD4 binding site.
doi:10.1371/journal.pone.0037530.g003
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infection of HIV-1 in vivo. Further study is necessary to address
above issue.
Thus far fine structures of neither the intact gp120 monomer
nor trimer are available. However, recent crystal structure study
disclosed a structure of V1/V2 domain [47], which had been the
major gp120 region lacking structural information. The V1/V2
domain is located on the outer surface of gp120, as is V3, and can
participate in phenotypic changes of HIV-1 [48,49]. In this regard,
Kwon et al [50] have found an intriguing role of gp120 variable
loops; gp120 core has an intrinsic preference to form the CD4-
bound conformation, whereas the variable loops, such as V1/V2
and V3 loops, play key roles in preventing conformational
transitions into the CD4-bound state that is sensitive to
neutralization. Thus it is conceivable that configurational changes
of V3 loop by V3 mutations play roles in modulating structural
dynamics of the unliganded gp120 core and neutralization
sensitivity of HIV-1. Availability of the V1/V2 loop structure will
promote structural study of the whole gp120 monomer containing
V3 loop, V1/V2 domain, and glycans. Our findings will provide a
structural basis to elucidate intra-molecular interactions of these
elements, which in turn will allow the study of structure, function,
and evolution of gp120 trimer. Incorporation of MD simulation
into these studies will help understanding structural dynamics with
which HIV-1 adjusts its relative replication fitness in nature.
Materials and Methods
Characteristics of the gp120 proteins and HIV-1s used
We used two isogenic recombinant gp120 proteins, termed
Gp120LAI-NH1V3 and Gp120LAI-TH09V3 [35], for the present
structural and neutralization studies. They differ only in their
V3 loops. The Gp120LAI-NH1V3 and Gp120LAI-TH09V3 have the
35-amino-acid-length V3 loops from HIV-1-infected individuals in
the gp120 backbone of the HIV-1LAI strain [35]. The net charges
of the V3 loops are +7 and +3 for the Gp120LAI-NH1V3 and
Gp120LAI-TH09V3, respectively (the V3 net charge represents the
number of positively charged amino acids (R, K, and H) minus the
number of negatively charged amino acids (D and E) in the V3
loop). The HIV-1LAI carrying the Gp120LAI-NH1V3 (HIV-1LAI-
NH1V3) is the CXCR4 tropic virus, whereas that carrying the
Gp120LAI-TH09V3 (HIV-1LAI-TH09V3) is the CCR5 monotropic
virus [35]. The HIV-1LAI-NH1V3 is sensitive to neutralization by
antibodies with the ability to bind to the peptides containing the
autologous V3 tip sequences, whereas HIV-1LAI-TH09V3 is highly
resistant to antibodies targeting the autologous V3 tip sequences
[13].
MD simulation
As the initial structures for the MD simulation, we first
constructed three-dimensional (3-D) models of the outer domains
of the Gp120LAI-NH1V3 and Gp120LAI-TH09V3 by the comparative
(homology) modeling method (reviewed in [33,51,52]), as
described previously [13]. We used the crystal structure of HIV-
1 gp120 containing an entire V3 region at a resolution of 3.30 A ˚
(PDB code: 2B4C [1]) as the modeling template. The gp120 core is
in complex with the CD4 receptor and the CD4 induced structure
(CD4i) antibody X5 [1]: it represents the structure after the CD4
binding. We deleted the structures of the CD4 receptor and the
X5 antibody from the 2B4C complex structure to construct the
free gp120 outer domain models of HIV-1LAI V3 recombinant
viruses by homology modeling. Then the models were subjected to
the MD simulations to analyze structure and dynamics of the
gp120 outer domain in the absence of the CD4 receptor and the
X5 antibody interactions. The homology modeling was performed
using tools available in the Molecular Operating Environment
(MOE) program (MOE 2008.10; Chemical Computing Group
Inc., Montreal, Quebec, Canada). The 186 amino-terminal and
27 carboxyl-terminal residues were deleted to construct the gp120
outer domain structure. We optimized the 3-D structure
thermodynamically via energy minimization using an MOE and
an AMBER99 force field [53]. We further refined the physically
unacceptable local structure of the models based on a Ramachan-
dran plot evaluation using MOE. MD simulations were performed
as described previously [13] using the Sander module in the
Amber 9 program package [54] and the AMBER99SB force field
[55] with the TIP3P water model [56]. Bond lengths involving
hydrogen were constrained with the SHAKE algorithm [57], and
the time step for all MD simulations was set to 2 fs. A nonbonded
cutoff of 12 A ˚ was used. After heating calculations for 20 ps to
310 K using the NVT ensemble, the simulations were executed
using the NPT ensemble at 1 atm at 310 K for 30 ns.
Superimpositions of the Gp120LAI-NH1V3 and Gp120LAI-TH09V3
structures were done by coordinating atoms of amino acids along
the b-sheet at the gp120 outer domain. We performed two
independent MD simulations with distinct MD codes and
obtained similar results. Therefore, we present here the data set
from one of the MD simulations as a representation.
Calculation of the root mean square deviation (RMSD)
and root mean square fluctuation (RMSF)
The RMSD values between the heavy atoms of the two
superposed proteins were used to measure the overall structural
differences between the two proteins [34]. We also calculated the
RMSF to provide information about the atomic fluctuations
during MD simulations [34]. In this study, we calculated the
RMSF of the main chains of individual amino acids using the
40,000 snapshots obtained from MD simulations of 10–30 ns. The
average structures during the last 20 ns of MD simulations were
used as reference structures for the calculation of the RMSF. Both
the RMSD and RMSF were calculated using the ptraj module in
Amber 9 [34].
Monoclonal antibodies (MAbs)
The 49G2, 42F9, 0.5d and 4C11 antibodies used for the
neutralization assay were the human MAbs established from an
HIV-1-infected patient with long-term non-progressive illness.
Human blood samples were collected after signed informed
consent in accordance with study protocol and informed consent
reviewed and approved by Ethics committee for clinical research
& advanced medical technology at the Faculty of Life Science
Kumamoto University. B cells from the patient’s peripheral blood
mononuclear cells were transformed by EBV, followed by cloning
as described previously [58]. The culture supernatant from an
individual clone was screened for the reactivity to gp120SF2 by an
enzyme-linked immunosorbent assay (ELISA). The specificity of
antibodies was determined by gp120 capture ELISA and FACS
analysis as described previously [59]. Briefly, reactivity of the
mAbs against monomeric gp120 of HIV-1SF2 was measured with a
gp120 capture assay in the absence or presence of soluble CD4
(0.5 mg/ml). Decrease in the binding activity was observed for the
mAbs 0.5d, 49G2, and 42F9 in the presence of soluble CD4,
whereas enhancement in the reactivity was detected for the mAb
4C11. Reactivity of the mAbs against envelope protein on the cell
surface was measured with a FACS analysis of PM1 cells
chronically infected with JR-FL in the absence or presence of
soluble CD4 (0.5 mg/ml). No significant difference was observed
for the binding profiles of 0.5d, 49G2, and 42F9 in the presence of
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observed for the 4C11 in the presence of soluble CD4. Based on
these binding data, we classified 49G2, 42F9, and 0.5d as CD4
binding site Mabs, and 4C11 as a CD4-induced epitope. All MAbs
used in this study were purified by affinity chromatography on
Protein A Sepharose. A human MAb 8D11 was used as a negative
control for the neutralization assay. Mouse MAb 4301 was
purchased from Advanced BioScience Laboratories, Inc. (Ken-
sington, MD). The 4301 was raised with a mixture of purified
gp120 of HIV-1IIIB and HIV-1MN and broadly reactive with the
gp120 of different HIV-1 isolates [37].
Neutralization assay
We used the two above-described V3 recombinant HIV-1s,
HIV-1LAI-NH1V3 and HIV-1LAI-TH09V3 [35], for the neutralization
study. The HIV-1 cell-free viruses were prepared by transfection
of the plasmid DNAs into HeLa cells as described previously
[24,35,60]. The neutralization activities of antibodies were
measured in a single-round viral infectivity assay using
CD4
+CXCR4
+CCR5
+ HeLa cells [36] as described previously
[13]. Briefly, equal infectious titers of viruses (300 blue-cell-
forming units) were incubated with serially diluted MAb prepa-
rations (0.03–10 mg/ml) for 1 hour at 37uC. The cells were
infected with the virus-antibody mixture for 48 hours at 37uC,
fixed, and stained with 5-bromo-4-chloro-3-indolyl-b-D-galacto-
pyranoside. Each antibody dilution was tested in duplicate, and
the means of the positive blue cell numbers were used to calculate
the 50% inhibition dose of viral infectivity (ND50).
Analysis of amino acid diversity
Amino acid diversity at individual sites of the HIV-1 gp120
sequences was analyzed with Shannon entropy scores as described
previously [13,61,62]. Full-length gp120 amino acid sequences of
the HIV-1 subtypes CRF01_AE and C were obtained from the
HIV Sequence Database (http://www.hiv.lanl.gov/content/
sequence/HIV/mainpage.html). The sequences were divided into
subgroups based on the net charge of V3 loop (+2,+8) using a
software system, InforSense 5.0.1 (InforSense Ltd. http://www.
inforsense.com/); arginine (R), lysine (K), and histidine (H) were
counted as +1, aspartic acid (D) and glutamic acid (E) as -1, and
other amino acids as 0. The numbers of sequences used for the
analysis of CRF01_AE were 11, 81, 57, 28, 18, 9, and 4 for +2, +3,
+4, +5, +6, +7, and +8, respectively. The amino acid diversity
within each V3 subpopulation of the same HIV-1 subtype was
calculated using Shannon’s formula [63]:
H(i)~{
X
xi
p(xi)log2p(xi) xi~G, A, I, V, ...... fg ,
where H(i), p(xi), and i indicate the amino acid entropy score of a
given position, the probability of occurrence of a given amino acid
at the position, and the number of the position, respectively. An
H(i) score of zero indicates absolute conservation, whereas 4.4 bits
indicates complete randomness. The H(i) scores were displayed on
the 3-D structure of an HIV-1 gp120 (PDB code: 2B4C [1]).
Acknowledgments
We thank Shingo Kiyoura (SGI Japan, Ltd.), and Kaori Sawada and
Takashi Ikegami (Ryoka Systems Inc.) for their support with the
computational analysis. We thank Hirotaka Ode of the Pathogen
Genomics Center for his helpful comments on the manuscript.
Author Contributions
Conceived and designed the experiments: MY SN HS. Performed the
experiments: MY SN HS. Analyzed the data: MY SN HS. Contributed
reagents/materials/analysis tools: KY SM. Wrote the paper: MY HS.
References
1. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005)
Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025–1028.
2. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, et al. (2007) Structures of
the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120
and CD4. Science 317: 1930–1934.
3. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, et al. (1996) The beta-
chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1
isolates. Cell 85: 1135–1148.
4. Speck RF, Wehrly K, Platt EJ, Atchison RE, Charo IF, et al. (1997) Selective
employment of chemokine receptors as human immunodeficiency virus type 1
coreceptors determined by individual amino acids within the envelope V3 loop.
J Virol 71: 7136–7139.
5. Xiao L, Owen SM, Goldman I, Lal AA, deJong JJ, et al. (1998) CCR5
coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of
phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in
the V3 domain that predicts CCR-5 usage. Virology 240: 83–92.
6. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, et al. (1998)
Identification of determinants on a dualtropic human immunodeficiency virus
type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 72:
2509–2515.
7. Goudsmit J, Debouck C, Meloen RH, Smit L, Bakker M, et al. (1988) Human
immunodeficiency virus type 1 neutralization epitope with conserved architec-
ture elicits early type-specific antibodies in experimentally infected chimpanzees.
Proc Natl Acad Sci U S A 85: 4478–4482.
8. Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, et al. (1988)
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells
bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad
Sci U S A 85: 3198–3202.
9. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, et al. (1989)
Principal neutralizing domain of the human immunodeficiency virus type 1
envelope protein. Proc Natl Acad Sci U S A 86: 6768–6772.
10. Cavacini LA, Duval M, Robinson J, Posner MR (2002) Interactions of human
antibodies, epitope exposure, antibody binding and neutralization of primary
isolate HIV-1 virions. Aids 16: 2409–2417.
11. Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, et al. (2005) Cryptic nature
of a conserved, CD4-inducible V3 loop neutralization epitope in the native
envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using,
primary human immunodeficiency virus type 1 strains. J Virol 79: 6957–6968.
12. Bou-Habib DC, Roderiquez G, Oravecz T, Berman PW, Lusso P, et al. (1994)
Cryptic nature of envelope V3 region epitopes protects primary monocytotropic
human immunodeficiency virus type 1 from antibody neutralization. J Virol 68:
6006–6013.
13. Naganawa S, Yokoyama M, Shiino T, Suzuki T, Ishigatsubo Y, et al. (2008) Net
positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to
humoral immunity. PLoS One 3: e3206.
14. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR (1992) Identification of envelope
V3 loop as the major determinant of CD4 neutralization sensitivity of HIV-1.
Science 257: 535–537.
15. Willey RL, Theodore TS, Martin MA (1994) Amino acid substitutions in the
human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism
also alter physical and functional properties of the virion envelope. J Virol 68:
4409–4419.
16. Willey RL, Martin MA, Peden KW (1994) Increase in soluble CD4 binding to
and CD4-induced dissociation of gp120 from virions correlates with infectivity of
human immunodeficiency virus type 1. J Virol 68: 1029–1039.
17. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure
of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a
neutralizing human antibody. Nature 393: 648–659.
18. Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG, et al.
(1992) Phenotype-associated sequence variation in the third variable domain of
the human immunodeficiency virus type 1 gp120 molecule. J Virol 66:
3183–3187.
19. Chesebro B, Wehrly K, Nishio J, Perryman S (1992) Macrophage-tropic human
immunodeficiency virus isolates from different patients exhibit unusual V3
envelope sequence homogeneity in comparison with T-cell-tropic isolates:
definition of critical amino acids involved in cell tropism. J Virol 66: 6547–6554.
20. Milich L, Margolin B, Swanstrom R (1993) V3 loop of the human
immunodeficiency virus type 1 Env protein: interpreting sequence variability.
J Virol 67: 5623–5634.
21. Milich L, Margolin BH, Swanstrom R (1997) Patterns of amino acid variability
in NSI-like and SI-like V3 sequences and a linked change in the CD4-binding
domain of the HIV-1 Env protein. Virology 239: 108–118.
MD Simulation of HIV-1 gp120 Outer Domain with V3
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e3753022. de Jong J-J, de Ronde A, Keulen W, Tersmette M, Goudsmit J (1992) Minimal
requirements for the human immunodeficiency virus type 1 V3 domain to
support the syncytium-inducing phenotype: analysis by single amino acid
substitution. J Virol 66: 6777–6780.
23. Shioda T, Oka S, Ida S, Nokihara K, Toriyoshi H, et al. (1994) A naturally
occurring single basic amino acid substitution in the V3 region of the human
immunodeficiency virus type 1 env protein alters the cellular host range and
antigenic structure of the virus. J Virol 68: 7689–7696.
24. Kato K, Sato H, Takebe Y (1999) Role of naturally occurring basic amino acid
substitutions in the human immunodeficiency virus type 1 subtype E envelope
V3 loop on viral coreceptor usage and cell tropism. J Virol 73: 5520–5526.
25. Thorpe IF, Brooks CL, 3rd (2007) Molecular evolution of affinity and flexibility
in the immune system. Proc Natl Acad Sci U S A 104: 8821–8826.
26. Lu HP, Xun L, Xie XS (1998) Single-molecule enzymatic dynamics. Science
282: 1877–1882.
27. Astumian RD (1997) Thermodynamics and kinetics of a Brownian motor.
Science 276: 917–922.
28. Garcia-Viloca M, Gao J, Karplus M, Truhlar DG (2004) How enzymes work:
analysis by modern rate theory and computer simulations. Science 303:
186–195.
29. Karplus M, Kuriyan J (2005) Molecular dynamics and protein function. Proc
Natl Acad Sci U S A 102: 6679–6685.
30. Dodson GG, Lane DP, Verma CS (2008) Molecular simulations of protein
dynamics: new windows on mechanisms in biology. EMBO Rep 9: 144–150.
31. Miyamoto T, Yokoyama M, Kono K, Shioda T, Sato H, et al. (2011) A single
amino acid of human immunodeficiency virus type 2 capsid protein affects
conformation of two external loops and viral sensitivity to TRIM5alpha. PLoS
One 6: e22779.
32. Ode H, Yokoyama M, Kanda T, Sato H (2011) Identification of folding
preferences of cleavage junctions of HIV-1 precursor proteins for regulation of
cleavability. J Mol Model 17: 391–399.
33. Baker D, Sali A (2001) Protein structure prediction and structural genomics.
Science 294: 93–96.
34. Case DA, Cheatham TE, 3rd, Darden T, Gohlke H, Luo R, et al. (2005) The
Amber biomolecular simulation programs. J Comput Chem 26: 1668–1688.
35. Sato H, Kato K, Takebe Y (1999) Functional complementation of the envelope
hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by
the subtype E V3 loop. Virology 257: 491–501.
36. Hachiya A, Aizawa-Matsuoka S, Tanaka M, Takahashi Y, Ida S, et al. (2001)
Rapid and simple phenotypic assay for drug susceptibility of human
immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell
clone 1–10 (MAGIC-5). Antimicrob Agents Chemother 45: 495–501.
37. di Marzo Veronese F, Rahman R, Pal R, Boyer C, Romano J, et al. (1992)
Delineation of immunoreactive, conserved regions in the external glycoprotein
of the human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 8:
1125–1132.
38. Simmonds P, Balfe P, Ludlam CA, Bishop JO, Brown AJ (1990) Analysis of
sequence diversity in hypervariable regions of the external glycoprotein of
human immunodeficiency virus type 1. J Virol 64: 5840–5850.
39. Burns DP, Desrosiers RC (1994) Envelope sequence variation, neutralizing
antibodies, and primate lentivirus persistence. Curr Top Microbiol Immunol
188: 185–219.
40. Bonhoeffer S, Holmes SE, Nowak M (1995) Causes of HIV diversity. Nature
376: 125.
41. Lukashov VV, Kuiken CL, Goudsmit J (1995) Intrahost human immunodefi-
ciency virus type 1 evolution is related to length of the immunocompetent
period. J Virol 69: 6911–6916.
42. Buonaguro L, Tornesello ML, Buonaguro FM (2007) Human immunodeficien-
cy virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and
therapeutic implications. J Virol 81: 10209–10219.
43. Brown LS, Kamikubo H, Zimanyi L, Kataoka M, Tokunaga F, et al. (1997) A
local electrostatic change is the cause of the large-scale protein conformation
shift in bacteriorhodopsin. Proc Natl Acad Sci U S A 94: 5040–5044.
44. Wu SR, Loving R, Lindqvist B, Hebert H, Koeck PJ, et al. (2010) Single-particle
cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure.
Proc Natl Acad Sci U S A 107: 18844–18849.
45. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, et al. (2010)
Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on
intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog
6: e1001249.
46. Hu G, Liu J, Taylor KA, Roux KH (2011) Structural comparison of HIV-1
envelope spikes with and without the V1/V2 loop. J Virol 85: 2741–2750.
47. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2012) Structure
of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9.
Nature 480: 336–343.
48. Shibata J, Yoshimura K, Honda A, Koito A, Murakami T, et al. (2007) Impact
of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal
antibody during in vitro selection of a primary human immunodeficiency virus
type 1 isolate. J Virol 81: 3757–3768.
49. Ogert RA, Lee MK, Ross W, Buckler-White A, Martin MA, et al. (2001) N-
linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of
dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect
coreceptor usage and cellular tropism. J Virol 75: 5998–6006.
50. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, et al. (2012) Unliganded
HIV-1 gp120 core structures assume the CD4-bound conformation with
regulation by quaternary interactions and variable loops. Proc Natl Acad
Sci U S A 109: 5663–5668.
51. Sanchez R, Pieper U, Melo F, Eswar N, Marti-Renom MA, et al. (2000) Protein
structure modeling for structural genomics. Nat Struct Biol 7 Suppl: 986–990.
52. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, et al. (2000)
Comparative protein structure modeling of genes and genomes. Annu Rev
Biophys Biomol Struct 29: 291–325.
53. Ponder JW, Case DA (2003) Force fields for protein simulations. Adv Protein
Chem 66: 27–85.
54. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, et al. (2006)
AMBER 9. University of California: San Francisco.
55. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison
of multiple Amber force fields and development of improved protein backbone
parameters. Proteins 65: 712–725.
56. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983)
Comparison of simple potential functions for simulating liquid water. J Chem
Phys 79: 926–935.
57. Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical integration of the
Cartesian equations of motion of a system with constraints: Molecular dynamics
of n-alkanes. J Comput Phys 23: 327–341.
58. Matsushita S, Robert-Guroff M, Rusche J, Koito A, Hattori T, et al. (1988)
Characterization of a human immunodeficiency virus neutralizing monoclonal
antibody and mapping of the neutralizing epitope. J Virol 62: 2107–2114.
59. Yoshimura K, Harada S, Shibata J, Hatada M, Yamada Y, et al. (2010)
Enhanced Exposure of Human Immunodeficiency Virus Type 1 Primary Isolate
Neutralization Epitopes through Binding of CD4 Mimetic Compounds. J Virol.
60. Shiino T, Kato K, Kodaka N, Miyakuni T, Takebe Y, et al. (2000) A group of
V3 sequences from human immunodeficiency virus type 1 subtype E non-
syncytium-inducing, CCR5-using variants are resistant to positive selection
pressure. J Virol 74: 1069–1078.
61. Motomura K, Oka T, Yokoyama M, Nakamura H, Mori H, et al. (2008)
Identification of monomorphic and divergent haplotypes in the 2006–2007
norovirus GII/4 epidemic population by genomewide tracing of evolutionary
history. J Virol 82: 11247–11262.
62. Oka T, Yokoyama M, Katayama K, Tsunemitsu H, Yamamoto M, et al. (2009)
Structural and biological constraints on diversity of regions immediately
upstream of cleavage sites in calicivirus precursor proteins. Virology 394:
119–129.
63. Shannon CE (1997) The mathematical theory of communication. 1963. MD
Comput 14: 306–317.
MD Simulation of HIV-1 gp120 Outer Domain with V3
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37530